We are live on ! Find out more
ZBIO

ProShares UltraPro Short NASDAQ Biotechnology
ZBIO

Delisted

ZBIO was delisted on the 27th of March, 2020.

Back to rankings

3 hedge funds and large institutions have $1.41M invested in ProShares UltraPro Short NASDAQ Biotechnology in 2015 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

409% more capital invested

Capital invested by funds: $277K → $1.41M (+$1.13M)

200% more funds holding

Funds holding: 1 → 3 (+2)

101% more call options, than puts

Call options by funds: $823K | Put options by funds: $410K

Holders
3
Holders Change
+2
Holders Change %
+200%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
–
Closed
–
Calls
$823K
Puts
$410K
Net Calls
+$413K
Net Calls Change
+$413K

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$467K
2
Jane Street
Jane Street
New York
+$214K
3
TRCT
Tower Research Capital (TRC)
New York
+$10.7K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
VF
1
Virtu Financial
New York
$1.08M +$467K +10,279 +164%
Jane Street
2
Jane Street
New York
$309K +$214K +4,705 New
TRCT
3
Tower Research Capital (TRC)
New York
$16K +$10.7K +236 New

ZBIO Hedge Fund Activity: Q3 2015 in Review

3 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) for Q3 2015, worth a combined $1.41M — up 409% from $277K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new ZBIO positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Virtu Financial, adding an estimated $467K.

  • 3 institutional investors held ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) as of Q3 2015, up from 1 in Q2 2015.
  • Funds reported $1.41M of ProShares UltraPro Short NASDAQ Biotechnology stock for Q3 2015, up 409% quarter-over-quarter.
  • 2 funds opened new ProShares UltraPro Short NASDAQ Biotechnology positions in Q3 2015 and 0 closed out, a net change of +2 holders.
  • The largest ProShares UltraPro Short NASDAQ Biotechnology buyer in Q3 2015 was Virtu Financial, an estimated $467K added.

Based on aggregated 13F filings for Q3 2015.